Literature DB >> 26968599

Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction.

B Smyth1, S Ong1.   

Abstract

We present the case of a 59-year-old woman with chronic kidney disease who suffered severe hypocalcaemia and hypophosphataemia after receiving denosumab and intravenous iron. This potentially life-threatening adverse drug interaction has never been reported before. We propose a mechanism to explain it with reference to the physiological derangements caused by both agents on calcium and phosphate homeostasis.
© 2016 Royal Australasian College of Physicians.

Entities:  

Keywords:  chronic kidney disease; denosumab; hypocalcaemia; hypophosphataemia; intravenous iron; iron polymaltose

Mesh:

Substances:

Year:  2016        PMID: 26968599     DOI: 10.1111/imj.13001

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

Review 1.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

2.  A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor.

Authors:  Young Jong Ko; Hong Moon Sohn; Yuria Jang; Mineon Park; Bora Kim; Beomchang Kim; Jae-Il Park; Hoon Hyun; Byeongseok Jeong; Chansik Hong; Wonbong Lim
Journal:  Clin Transl Med       Date:  2021-03

3.  High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.

Authors:  Johannes M M Boots; Rogier A M Quax
Journal:  Drug Saf       Date:  2022-09-06       Impact factor: 5.228

4.  Severe hypocalcaemia following denosumab and iron infusion.

Authors:  Adrienne Cohen; Bobby Chacko
Journal:  Nephrology (Carlton)       Date:  2022-06-23       Impact factor: 2.358

5.  High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.

Authors:  Koji Ishikawa; Takashi Nagai; Koki Tsuchiya; Yusuke Oshita; Takuma Kuroda; Hiroshi Ito; Soji Tani; Yusuke Dodo; Tomoaki Toyone; Katsunori Inagaki
Journal:  Clin Interv Aging       Date:  2018-10-08       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.